Search

Your search keyword '"COLECCHIA, ANTONIO"' showing total 103 results
Start Over Author "COLECCHIA, ANTONIO" Publisher elsevier b.v.
103 results on '"COLECCHIA, ANTONIO"'

2. Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis

Author

Iannone, Giulia, Serri, Paola, Bertino, Gaetano, Balsano, Clara, Iapadre, Nerio, Maida, Marcello, Sacerdoti, David, Natola, Leonardo Antonio, Ciacci, Carolina, Santonicola, Antonella, Cozzolongo, Raffaele, Surace, Lorenzo Antonio, Fracanzani, Anna Ludovica, Cespiati, Annalisa, Federico, Alessandro, Romeo, Mario, Grieco, Antonio, Marrone, Giuseppe, Vizioli, Luca, Di Cola, Simone, D’Amico, Gennaro, Caraceni, Paolo, Schepis, Filippo, Loredana, Simone, Lampertico, Pietro, Toniutto, Pierluigi, Martini, Silvia, Maimone, Sergio, Colecchia, Antonio, Svegliati Barone, Gianluca, Alessandria, Carlo, Aghemo, Alessio, Crocè, Saveria Lory, Adinolfi, Luigi Elio, Rendina, Maria, Lapenna, Lucia, Pompili, Enrico, Zaccherini, Giacomo, Saltini, Dario, Iavarone, Massimo, Tosetti, Giulia, Martelletti, Carolina, Nassisi, Veronica, Ferrarese, Alberto, Giovo, Ilaria, Masetti, Chiara, Pugliese, Nicola, Campigotto, Michele, Nevola, Riccardo, and Merli, Manuela

Published
2024
Full Text
View/download PDF

4. Exploring algorithms to select candidates for non-selective beta-blockers in cirrhosis: A post hoc analysis of the PREDESCI trial

Author

Villanueva, Càndid, Albillos, Agustín, Genescà, Joan, Garcia-Pagan, Juan C., Calleja, José L., Aracil, Carles, Bañares, Rafael, Morillas, Rosa M., Poca, María, Peñas, Beatriz, Augustin, Salvador, Abraldes, Juan G., Alvarado, Edilmar, Torres, Ferran, Bosch, Jaume, Dajti, Elton, Berzigotti, Annalisa, Brujats, Anna, García-Pagán, Juan C., and Colecchia, Antonio

Published
2024
Full Text
View/download PDF

5. Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease

Author

Pennisi, Grazia, Enea, Marco, Viganò, Mauro, Schepis, Filippo, de Ledinghen, Victor, Berzigotti, Annalisa, Wai-Sun Wong, Vincent, Fracanzani, Anna Ludovica, Sebastiani, Giada, Lara-Romero, Carmen, Bugianesi, Elisabetta, Svegliati-Baroni, Gianluca, Marra, Fabio, Aghemo, Alessio, Valenti, Luca, Calvaruso, Vincenza, Colecchia, Antonio, Di Maria, Gabriele, La Mantia, Claudia, Lin, Huapeng, Mendoza, Yuly P., Pugliese, Nicola, Ravaioli, Federico, Romero-Gomez, Manuel, Saltini, Dario, Craxì, Antonio, Di Marco, Vito, Cammà, Calogero, and Petta, Salvatore

Published
2023
Full Text
View/download PDF

8. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma

Author

Cabibbo, Giuseppe, Petta, Salvatore, Barbara, Marco, Attardo, Simona, Bucci, Laura, Farinati, Fabio, Giannini, Edoardo G., Negrini, Giulia, Ciccarese, Francesca, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Sacco, Rodolfo, Virdone, Roberto, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Benvegnù, Luisa, Gasbarrini, Antonio, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Olivani, Andrea, Masotto, Alberto, Nardone, Gerardo, Colecchia, Antonio, Persico, Marcello, Craxì, Antonio, Trevisani, Franco, and Cammà, Calogero

Published
2017
Full Text
View/download PDF

9. Evolution of liver fibrosis in diabetic patients with NAFLD in a follow-up study: Hepatoprotective effects of sodium-glucose co-transporter-2 inhibitors.

Author

Lombardi, Rosa, Mantovani, Alessandro, Cespiati, Annalisa, Francione, Paolo, Maffi, Gabriele, Del Zanna, Elena, Maffeis, Claudio, Colecchia, Antonio, Passigato, Nicola, Ferrarese, Alberto, Cusumanu, Caterina Daniela, Villani, Rosanna, Orsi, Emanuela, Grancini, Valeria, Airaghi, Lorena, Bignamini, Daniela, Serviddio, Gaetano, Targher, Giovanni, Dongiovanni, Paola, and Fargion, Silvia

Abstract

Patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are at high risk of hepatic fibrosis. To prospectively evaluate changes in fibrosis in diabetic patients with NAFLD, predisposing factors and sodium glucose cotransporter 2 inhibitors (SGLT2i) influence. 237 T2DM outpatients (mean age 67 ± 9 years, 54% male) were enrolled and re-evaluated after 52 ± 10 months. At baseline and follow-up NAFLD and liver fibrosis (LSM) were detected by ultrasonography and Fibroscan®. During follow-up an increase in LSM (6.0 ± 2.8 vs 5.8 ± 2.7 kPa, p = 0.02) and in the prescription of SGLT2i (20% vs 6%, p <0.001) was registered, despite stability of diabetic control. LSM worsened in 133(56%) subjects, 92 (39%) with worsening >10% from baseline. Patients with worsening versus non worsening of LSM had higher prevalence of increase in BMI during follow-up (45% vs 32%, p = 0.06) and lower SGLT2i prescription (15% vs 27%, p = 0.034). In multivariate analysis use of SGLT2-inhibitors at follow-up reduced the risk of LSM worsening (HR 0.34, 95% CI 0.13–0.88), even when considered>10% from baseline. A high prevalence of fibrosis progression was observed in diabetic subjects with NAFLD over a nearly 5-years follow up and SGLT2-inhibitors seem to reduce the risk of worsening of liver stiffness. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. TOP-143-YI Porto-sinusoidal vascular disease among patients undergoing surgery for liver metastases: prevalence, non-invasive diagnosis, and burden on surgical outcomes

Author

Dajti, Elton, Serenari, Matteo, Malvi, Deborah, Dajti, Gerti, Ravaioli, Federico, Colecchia, Luigi, Marasco, Giovanni, Odaldi, Federica, Renzulli, Matteo, Vestito, Amanda, Azzaroli, Francesco, Barbara, Giovanni, Ravaioli, Matteo, Festi, Davide, D'Errico, Maria Antonietta, Cescon, Matteo, and Colecchia, Antonio

Published
2024
Full Text
View/download PDF

14. SAT-490 Competitive risk analysis of spleen stiffness measurement with a spleen-dedicated module (SSM@100 Hz) for predicting de-novo HCC occurrence in cACLD patients: a prospective 5-year follow-up study

Author

Ravaioli, Federico, Colecchia, Luigi, Dajti, Elton, Vestito, Amanda, Gobbato, Arianna, Lami, Francesca, Renzulli, Matteo, Serenari, Matteo, Di Marco, Lorenza, Tovoli, Francesco, Ferri, Silvia, Pivetti, Alessandra, Romagnoli, Dante, Azzaroli, Francesco, Festi, Davide, Colecchia, Antonio, and Marasco, Giovanni

Published
2024
Full Text
View/download PDF

17. SAT-068 Accuracy of spleen stiffness measurement for the diagnosis of high-risk esophageal varices in patients with advanced chronic liver disease: a systematic review and individual patient data meta-analysis

Author

Dajti, Elton, Ravaioli, Federico, Qi, Xiaolong, Chen, Jinjun, ştefănescu, Horia, Seo Cho, Young, Cassinotto, Cristophe, Gaspar, Rui, Lory Croce’, Saveria, Elsabaawy, Maha, Fraquelli, Mirella, Grgurevic, Ivica, Braticevici, Carmen Fierbinteanu, Wong, Grace, Bende, Renata, Janik, Maciej, Fernandes, Flavia, Elkrief, Laure, Rautou, Pierre-Emmanuel, Nakajima, Atsushi, Zykus, Romanas, Buechter, Matthias, Galati, Giovanni, Reiberger, Thomas, Lusina, Ekaterina, Anta, Julia Arribas, Fortea, Jose Ignacio, Chang, Jason Pik Eu, Lucchina, Natalie, Masashi, Hirooka, Soardo, Giorgio, Colecchia, Luigi, Roccarina, Davide, Piscaglia, Fabio, Azzaroli, Francesco, Marasco, Giovanni, Colli, Agostino, Festi, Davide, Berzigotti, Annalisa, and Colecchia, Antonio

Published
2024
Full Text
View/download PDF

18. OS-099-YI Assessment of sarcopenia improves the prediction of post-TIPS mortality in older adult patients with cirrhosis

Author

Saltini, Dario, Nardelli, Silvia, Vizzutti, Francesco, Miraglia, Roberto, Bellafante, Daniele, Banchelli, Federico, Caporali, Cristian, Maruzzelli, Luigi, Falcone, Gianmarco, Bianchini, Marcello, Cuffari, Biagio, Guasconi, Tomas, Ingravallo, Angelica, Casari, Federico, Indulti, Federica, Francesco, Prampolini, Colecchia, Antonio, Marra, Fabio, Camma, Calogero, Senzolo, Marco, Riggio, Oliviero, and Schepis, Filippo

Published
2024
Full Text
View/download PDF

19. OS-096-YI Spleen stiffness measurement by transient elastography at 100 Hz refines the non-invasive diagnosis of clinically significant portal hypertension in compensated advanced chronic liver diseasefinal results of a european multicenter study

Author

Jachs, Mathias, Moga, Lucile, Kwanten, Wilhelmus J, Fischer, Petra, Odriozola, Aitor, Turon, Fanny, Saltini, Dario, Téllez, Luis, Armandi, Angelo, Mendoza, Yuly, Herrera, Elba Llop, Grasso, Maria, Dajti, Elton, Vanderschueren, Emma, Sandmann, Lisa, Thalhammer, Julia, Pardo, Carlos, Schoenmakers, Lotte, Vanwolleghem, Thomas, Vonghia, Luisa, Labenz, Christian, Semmler, Georg, Hartl, Lukas, Maasoumy, Benjamin, Laleman, Wim, Ravaioli, Federico, Presa, José, Calvaruso, Vincenza, Panero, José Luis Calleja, Berzigotti, Annalisa, Schattenberg, Jörn M, Albillos, Agustín, Colecchia, Antonio, Schepis, Filippo, García-Pagán, Juan Carlos, Puente, Angela, Fortea, Jose Ignacio, Procopet, Bogdan, Francque, Sven, Rautou, Pierre-Emmanuel, Reiberger, Thomas, and Mandorfer, Mattias

Published
2024
Full Text
View/download PDF

22. The interplay between sarcopenia and portal hypertension predicts ascites and mortality in cirrhosis.

Author

Dajti, Elton, Renzulli, Matteo, Ravaioli, Federico, Marasco, Giovanni, Vara, Giulio, Brandi, Nicolò, Rossini, Benedetta, Colecchia, Luigi, Alemanni, Luigina Vanessa, Ferrarese, Alberto, Vestito, Amanda, Tamè, Mariarosa, Azzaroli, Francesco, Festi, Davide, Golfieri, Rita, and Colecchia, Antonio

Abstract

The role of sarcopenia in predicting decompensation other than hepatic encephalopathy is unclear. We aimed to evaluate the prognostic role of sarcopenia, assessed by computed tomography (CT), in the development of ascites and mortality in patients with advanced chronic liver disease (ACLD) outside the liver transplantation (LT) setting. We retrospectively evaluated ACLD patients with liver stiffness measurement (LSM) >10 kPa and an available CT scan within 6 months. Sarcopenia was defined as skeletal muscle index (SMI) <50 and <39 cm2/m2, respectively, in men and women. Competing risk regression models were used to assess the variables associated with the main outcomes. 209 patients were included in the final analysis and sarcopenia was present in 134 (64.1%). During a median follow-up of 37 (20–63) months, 52 patients developed ascites, 24 underwent LT, and 30 died. Sarcopenia was found a predictive factor of decompensation with ascites (SHR 2.083, 95%-CI: 1.091–3.978), independently from the features of clinically significant portal hypertension (LSM≥21 kPa or portosystemic shunts). Sarcopenia (SHR: 2.744, 95%-CI: 1.105–6.816) and LSM≥21 kPa (SHR: 3.973, 95%-CI: 1.548–10.197) were independent risk factors for increased mortality. Sarcopenia and portal hypertension are two major and independent risk factors for decompensation with ascites and mortality in cirrhotic patients outside the LT context. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

25. THU-421 - Presence and severity of esophageal varices drives portal hypertension-related complications in compensated advanced non-alcoholic fatty liver disease

Author

Pennisi, Grazia, Enea, Marco, Viganò, Mauro, Schepis, Filippo, de Lédinghen, Victor, Berzigotti, Annalisa, Wong, Vincent Wai-Sun, Fracanzani, Anna Ludovica, Sebastiani, Giada, Gomez, Manuel Romero, Bugianesi, Elisabetta, Svegliati-Baroni, Gianluca, Marra, Fabio, Aghemo, Alessio, Valenti, Luca, Calvaruso, Vincenza, Colecchia, Antonio, Di Maria, Gabriele, La Mantia, Claudia, Lin, Huapeng, Mendoza, Yuly, Pugliese, Nicola, Ravaioli, Federico, Lara-Romero, Carmen, Saltini, Dario, Craxi, Antonio, Di Marco, Vito, Camma, Calogero, and Petta, Salvatore

Published
2023
Full Text
View/download PDF

27. SAT-334 - TIPS under-dilation strategy with new controlled expansion endoprosthesis: a hemodynamic and imaging confirmation of its feasibility

Author

Saltini, Dario, Caporali, Cristian, Indulti, Federica, Bianchini, Marcello, Casari, Federico, Prampolini, Francesco, Felaco, Davide, Guasconi, Tomas, Cuffari, Biagio, Zanetto, Alberto, Guerrini, Gian Piero, De Maria, Nicola, Villa, Erica, Colecchia, Antonio, Di Benedetto, Fabrizio, and Schepis, Filippo

Published
2023
Full Text
View/download PDF

28. SAT-327 - Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with advanced chronic liver disease: an individual patient meta-analysis

Author

Dajti, Elton, Ravaioli, Federico, Zykus, Romanas, Elkrief, Laure, Rautou, Pierre-Emmanuel, Grgurevic, Ivica, Stefanescu, Horia, Hirooka, Masashi, Mirella, Fraquelli, Rosselli, Matteo, Eu Chang, Jason Pik, Borghi, Alberto, Reiberger, Thomas, Llop, Elba, Mueller, Sebastian, Marasco, Giovanni, Berzigotti, Annalisa, Colli, Agostino, Festi, Davide, and Colecchia, Antonio

Published
2023
Full Text
View/download PDF

29. OS-124-YI - Diagnosis by liver stiffness measurement of sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic stem cell transplantation: results from the Italian multicentric prospective study (ELASTOVOD)

Author

Ravaioli, Federico, Colecchia, Antonio, Barbato, Francesco, Peccatori, Jacopo, Grassi, Anna, Sarina, Barbara, Pompili, Maurizio, Sica, Simona, Locatelli, Franco, Cesaro, Simone, Nozzoli, Chiara, Iori, Anna Paola, Prezioso, Lucia, Santarone, Stella, Fagioli, Franca, Olivieri, Attilio, Vanni, Ester, Specchia, Giorgina, Benedetti, Edoardo, Zallio, Francesco, Pane, Fabrizio, Carobolante, Francesca, Menconi, Maria Cristina, Benedetti, Fabio, Patriarca, Francesca, Malagola, Michele, Varaldo, Riccardo, Onida, Francesco, Pavone, Vincenzo, Vestito, Amanda, Colecchia, Luigi, Dajti, Elton, Alemanni, Luigina Vanessa, Marasco, Giovanni, Ciceri, Fabio, Prete, Arcangelo, Pession, Andrea, Festi, Davide, and Bonifazi, Francesca

Published
2023
Full Text
View/download PDF

30. OS-121-YI - Performance of spleen stiffness measurement by vibration-controlled transient elastography to rule out high-risk varices in patients with porto-sinusoidal vascular disorder

Author

Moga, Lucile, Paradis, Valérie, Gudavalli, Koushik, Silva, Joel, Colecchia, Antonio, Ravaioli, Federico, Nicoara-Farcau, Oana, Tosetti, Giulia, Berzigotti, Annalisa, Procopet, Bogdan, Simón-Talero, Macarena, Turco, Laura, Capinha, Francisco, Elkrief, Laure, Ferrusquia Acosta, Jose Alberto, Goria, Odile, Balcar, Lorenz, Adrien, Lannes, Mallet, Vincent, Poujol-Robert, Armelle, Thabut, Dominique, Houssel-Debry, Pauline, Wong, Yu Jun, Reiberger, Thomas, Monllor-Nunell, Teresa, Vitale, Giovanni, Ferreira, Carlos Noronha, Vidal-González, Judit, Fodor, Andreea, Antonenko, Antonina, Caccia, Riccardo, Turon, Fanny, Dajti, Elton, Schepis, Filippo, Indulti, Federica, Macedo, Guilherme, Rampally, Sai Prasanth, Payancé, Audrey, Laurent, Castera, Valsan, Arun, Plessier, Aurélie, and Rautou, Pierre-Emmanuel

Published
2023
Full Text
View/download PDF

31. Size and location of spontaneous portosystemic shunts predict the risk of decompensation in cirrhotic patients.

Author

Dajti, Elton, Renzulli, Matteo, Colecchia, Antonio, Bacchi-Reggiani, Maria Letizia, Milandri, Matteo, Rossini, Benedetta, Ravaioli, Federico, Marasco, Giovanni, Alemanni, Luigina Vanessa, Ierardi, Anna Maria, Carrafiello, Gianpaolo, Pinzani, Massimo, Azzaroli, Francesco, Mazzella, Giuseppe, Golfieri, Rita, and Festi, Davide

Abstract

The prognostic role of spontaneous portosystemic shunts (SPSS) has been poorly investigated. To evaluate the impact of the presence of SPSS, as well as their characteristics, on the risk of decompensation. This is a retrospective cohort study of 235 advanced chronic liver disease (ACLD) patients with available imaging examination, transient elastography, and upper endoscopy. ACLD was defined as liver stiffness measurement (LSM) >10 kPa. Competitive risk analyses were performed to identify the factors associated with the main outcome. SPSS were reported in 141 (60%) of the patients. Non-viral etiology was independently associated with SPSS presence [Odds-Ratio (OR): 2.743;95%-Interval-of-Confidence (IC):1.129–6.664]. During a follow-up of 37 (20–63) months, SPSS were found predictors of any decompensation type [Subhazard Ratio (SHR):2.264; 95%-IC:1.259–4.071], independently from a history of decompensation or high-risk-varices presence. The risk of complications was higher in patients with large (SHR: 3.775; 95%-IC: 2.016–7.070) and multiple (SHR:3.832; 95%-IC: 2.004–7.330) shunts, and in those with gastrorenal shunts (SHR:2.636; 95%-IC:1.521–4.569). The presence, size, and number of SPSS predict not only the risk of hepatic encephalopathy but that of any type of decompensation across all stages of cirrhosis. Future studies should explore the possibility of treating shunts to prevent decompensation. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

34. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study.

Author

Marasco, Giovanni, Colecchia, Antonio, Bacchi Reggiani, Maria Letizia, Celsa, Ciro, Farinati, Fabio, Giannini, Edoardo Giovanni, Benevento, Francesca, Rapaccini, Gian Ludovico, Caturelli, Eugenio, Di Marco, Mariella, Biasini, Elisabetta, Marra, Fabio, Morisco, Filomena, Foschi, Francesco Giuseppe, Zoli, Marco, Gasbarrini, Antonio, Baroni, Gianluca Svegliati, Masotto, Alberto, Sacco, Rodolfo, and Raimondo, Giovanni

Abstract

Sorafenib is the gold standard therapy for the advanced hepatocellular carcinoma (HCC). No scoring/staging is universally accepted to predict the survival of these patients. To evaluate the accuracy of the available prognostic models for HCC to predict the survival of advanced HCC patients treated with Sorafenib included in the Italian Liver Cancer (ITA.LI.CA.) multicenter cohort. The performance of several prognostic scores was assessed through a Cox regression-model evaluating the C-index and the Akaike Information Criterion (AIC). Data of 1129 patients were analyzed. The mean age of patients was 61.6 years, and 80.8% were male. During a median follow-up period of 13 months, 789 patients died. The median period of Sorafenib administration was 4 months. All the prognostic scores were able to predict the overall survival (p <0.001) at univariate analysis, except the Albumin-Bilirubin score. The Italian Liver Cancer score (CLIP) yielded the highest accuracy (C-index 0.604, AIC 9898), followed by the ITA.LI.CA. prognostic score (C-index 0.599, AIC 9915). The CLIP score had the highest accuracy in predicting the overall survival of HCC patients treated with Sorafenib, although its performance remained poor. Further studies are needed to refine the current ability to predict the outcome of HCC patients undergoing Sorafenib. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

35. Imaging in Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.

Author

Chan, Sherwin S., Colecchia, Antonio, Duarte, Rafael F., Bonifazi, Francesca, Ravaioli, Federico, and Bourhis, Jean Henri

Subjects
*HEPATIC veno-occlusive disease, *CELL transplantation, *THERAPEUTICS, *EARLY diagnosis
Abstract

• Early detection and prompt treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) are critical to optimal management. • Recent criteria have suggested a role for imaging in diagnosing VOD/SOS. • Evidence supports the use of ultrasound to confirm diagnosis and monitor treatment. • Ultrasound elastography is promising in early VOD/SOS diagnosis/response evaluation. • Clinical studies validating use of imaging in management of VOD/SOS are needed. Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication of hematopoietic cell transplantation. Early diagnosis and, subsequently, earlier intervention have been shown to be beneficial to clinical outcomes. Diagnostic criteria from the European Society for Blood and Marrow Transplantation include recommendations on the use of imaging for diagnosis. This review discusses evidence on the use of imaging in the management of VOD/SOS and how imaging biomarkers can contribute to earlier diagnosis/treatment. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

38. THU225 - Recent trends and intention-to-treat survival of liver transplantation for non-alcoholic steatohepatitis: an Italian liver transplant registry study. On behalf of AISF, FIRE, SITO and CNT

Author

Vitale, Alessandro, Trapani, Silvia, Burra, Patrizia, Bertacco, Alessandra, Romagnoli, Renato, Martini, Silvia, De Simone, Paolo, Carrai, Paola, Cescon, Matteo, Morelli, Maria Cristina, De Carlis, Luciano, Belli, Luca Saverio, Gruttadauria, Salvatore, Volpes, Riccardo, Colledan, Michele, Fagiuoli, Stefano, Rossi, Giorgio, Donato, Maria Francesca, Di Benedetto, Fabrizio, De Maria, Nicola, Tedeschi, Umberto, Colecchia, Antonio, Ricci, Andrea, Cardillo, Massimo, and Cillo, Umberto

Published
2020
Full Text
View/download PDF

40. Liver Stiffness Measurement Allows Early Diagnosis of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Adult Patients Who Undergo Hematopoietic Stem Cell Transplantation: Results from a Monocentric Prospective Study.

Author

Colecchia, Antonio, Ravaioli, Federico, Sessa, Mariarosaria, Alemanni, Vanessa Luigina, Dajti, Elton, Marasco, Giovanni, Vestito, Amanda, Zagari, Rocco Maurizio, Barbato, Francesco, Arpinati, Mario, Cavo, Michele, Festi, Davide, and Bonifazi, Francesca

Subjects
*HEMATOPOIETIC stem cell transplantation, *HEPATIC veno-occlusive disease, *DIAGNOSIS, *EARLY diagnosis, *RECEIVER operating characteristic curves
Abstract

• Liver stiffness measurement (LSM) by transient elastography is a promising technique for early diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) in adults undergoing hematopoietic stem cell transplantation (HSCT). • LSM anticipates the VOD/SOS diagnosis with a gain at 2 to 12 days before clinical diagnosis. • LSM decreases after VOD/SOS-specific treatments. • LSM can discriminate between VOD/SOS and other post-HSCT complications. Veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), is a life-threatening complication affecting patients undergoing hematopoietic stem cell transplantation (HSCT). The survival rate is higher when specific therapy is initiated early; thus, improving early, noninvasive diagnosis of VOD/SOS is an important need. In an adult population undergoing HSCT, we aimed to assess the role of liver stiffness measurement (LSM), evaluated by transient elastography (TE), for diagnosing VOD/SOS. Between April 2016 and March 2018, 78 consecutive adult patients with indications for allogeneic HSCT were prospectively included. LSM was performed before HSCT and at days +9/10, +15/17, and +22/24 post-HSCT. New European Society for Blood and Marrow Transplantation criteria were used to establish VOD/SOS diagnosis. Four patients developed VOD/SOS (5.1%) during the study period, with a median time of +17 days post-HSCT. A sudden increase in LSM compared with previously assessed values and pre-HSCT values, was seen in all patients who developed VOD/SOS. LSM increases occurred from 2 to 12 days before clinical SOS/VOD appearance. The VOD/SOS diagnostic performance of increased LSM over pre-HSCT assessment showed an area under the receiver operating characteristic curve of 0.997 (sensitivity 75%; specificity 98.7%). LSM gradually decreased following successful VOD/SOS-specific treatment. Interestingly, LSM values did not increase significantly in patients experiencing hepatobiliary complications (according to the Common Terminology Criteria) other than VOD/SOS. LSM by TE can be considered a promising method to perform an early, preclinical diagnosis and follow-up of VOD/SOS. Image, graphical abstract [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

48. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals.

Author

Ravaioli, Federico, Conti, Fabio, Brillanti, Stefano, Andreone, Pietro, Mazzella, Giuseppe, Buonfiglioli, Federica, Serio, Ilaria, Verrucchi, Gabriella, Bacchi Reggiani, Maria Letizia, Colli, Agostino, Marasco, Giovanni, Colecchia, Antonio, and Festi, Davide

Abstract

Background Direct-acting antivirals (DAA) are an effective treatment for hepatitis C virus infection. However, sustained virologic response (SVR) after DAA treatment does not seem to reduce the risk of hepatocellular carcinoma (HCC) development in these patients. Liver stiffness measurement (LSM) may predict the risk of developing HCC in liver cirrhosis patients. Aims The aim of our study was to evaluate the role of LSM variation as predictor of HCC development in patients treated with DAA. Methods In 139 HCV-related cirrhotic patients, LSM and laboratory tests were carried out at baseline (BL) and at the end of DAA treatment (EOT). Patients were followed for at least 6 months after the EOT. LSM reduction was expressed as Delta LS (∆LS). Cox regression analysis was used to identify prognostic factors for HCC development after DAA. Results Median LSM values were significantly reduced from BL to EOT (from 18.6 to 13.8 kPa; p < 0.001). The median ∆LS was −26.7% (IQR: −38.4% −13.6%). During a median follow-up of 15 months after DAA treatment, 20 (14.4%) patients developed HCC. Significant LSM reduction was observed both in patients who developed HCC and in those who did not, but this was significantly lower in the patients who developed HCC (−18.0% vs −28.9% p = 0.005). At multivariate analysis, ∆LS lower than −30%, Child-Turcotte-Pugh-B and history of HCC were independently associated with HCC development. Conclusion Our results indicate that ∆LS is a useful non-invasive marker for predicting HCC development after DAA treatment. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

49. Ductal stones recurrence after extracorporeal shock wave lithotripsy for difficult common bile duct stones: Predictive factors.

Author

Muratori, Rosangela, Mandolesi, Daniele, Pierantoni, Chiara, Festi, Davide, Colecchia, Antonio, Mazzella, Giuseppe, Bazzoli, Franco, and Azzaroli, Francesco

Abstract

Background & purpose Extra-corporeal shock wave lithotripsy (ESWL) can be considered in difficult common bile duct stones (DCBDS), with a success rate greater than 90% but data on stone recurrence after ESWL are limited. We performed a retrospective analysis to evaluate long-term outcomes in patients who underwent ESWL for DCBDS. Methods From May 1992 to October 2012, patients who underwent ESWL treatment for DCBDS, not amenable to endoscopic extraction, were included. Data on long-term outcome were collected through phone interviews and medical records. Results A total of 201 patients with a successful clearance of DCBDS after ESWL were included. During a median follow-up period of 4.64 years, 40 patients (20%) developed a recurrence of bile duct stones. Logistic regression analysis showed that the common bile duct diameter, gallstones presence and the maximum stone size were significantly associated with recurrence. Conclusions We observed a recurrence rate of 20% over a median follow-up of 4 years. Gallbladder stones, stone size and a dilated common bile duct diameter are risk factors for recurrent stone formation, while ursodeoxycholic acid treatment did not influence recurrence in our population. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

50. Differences in liver stiffness values obtained with new ultrasound elastography machines and Fibroscan: A comparative study.

Author

Piscaglia, Fabio, Salvatore, Veronica, Mulazzani, Lorenzo, Cantisani, Vito, Colecchia, Antonio, Di Donato, Roberto, Felicani, Cristina, Ferrarini, Alessia, Gamal, Nesrine, Grasso, Valentina, Marasco, Giovanni, Mazzotta, Elena, Ravaioli, Federico, Ruggieri, Giacomo, Serio, Ilaria, Sitouok Nkamgho, Joules Fabrice, Serra, Carla, Festi, Davide, Schiavone, Cosima, and Bolondi, Luigi

Abstract

Background and aims Whether Fibroscan thresholds can be immediately adopted for none, some or all other shear wave elastography techniques has not been tested. The aim of the present study was to test the concordance of the findings obtained from 7 of the most recent ultrasound elastography machines with respect to Fibroscan. Methods Sixteen hepatitis C virus-related patients with fibrosis ≥2 and having reliable results at Fibroscan were investigated in two intercostal spaces using 7 different elastography machines. Coefficients of both precision (an index of data dispersion) and accuracy (an index of bias correction factors expressing different magnitudes of changes in comparison to the reference) were calculated. Results Median stiffness values differed among the different machines as did coefficients of both precision (range 0.54–0.72) and accuracy (range 0.28–0.87). When the average of the measurements of two intercostal spaces was considered, coefficients of precision significantly increased with all machines (range 0.72–0.90) whereas of accuracy improved more scatteredly and by a smaller degree (range 0.40–0.99). Conclusions The present results showed only moderate concordance of the majority of elastography machines with the Fibroscan results, preventing the possibility of the immediate universal adoption of Fibroscan thresholds for defining liver fibrosis staging for all new machines. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results